Rapid Preclinical Formulation Screening
Obtaining formulations for preclinical safety and efficacy studies is often a time consuming and challenging task. This is made especially more difficult for today’s researchers as over 90 % of molecules currently in development experience low solubility characteristics.
In order to help facilitate the development of such compounds, scientists at Kuecept have implemented the award winning Solent™ Rapid Formulation Screening Service, which combines years of research in drug solubilisation technologies, excipient safety profiling and process miniaturisation. All formulations are specially designed taking into account the test compound's physico-chemical properties, desired adminstration route, target model species and dosing protocol, ensuring formulations are safe and robust for your preclinical needs.
Solent™ screens generally fall into two catagories:
- Solent™ Oral
- Solent™ Parenteral (IV (bolus and infusion), SC and IM)
The output from an individual Solent™ screen is a recommendation for suitable enabling formulations to support a full preclinical dosing program. Test formulations can be manufactured at our facilities and supplied directly to your preclinical testing facility, with supporting stability data to match planned study timelines. Alternatively, recipes, processes and excipients can also be supplied.
For more information on the specific services offered, please click on the relevant link above.
